Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cancer Therapy Reviews
  4. Volume 21, Issue 1
  5. Article
Volume 21, Issue 1
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

Introduction

Cyclin-dependent kinases (CDKs) are serine/threonine kinase proteins that regulate the cell cycle through phosphorylation and dephosphorylation. These proteins are a main target in cancer therapy. This study investigated the effect of omeprazole on CDK2, CDK4, and CDK6 through simulation studies.

Methods

To investigate the interaction between omeprazole and CDK2, 4, and 6, the three-dimensional structure of omeprazole was obtained from PubChem, and the structures of CDK2, 4, and 6 were acquired from RCSB servers. The proteins were then simulated for 50 nanoseconds using the GROMACS 2021 platform before the docking process. Next, Autodock v.4.2.6 software was used to bind omeprazole as a ligand to these proteins, and a molecular dynamics simulation of the resulting protein-ligand complex was conducted using GROMACS after the docking process.

Results

Omeprazole exhibited a high affinity for interacting with CDK2, 4, and 6, mainly occurring in the ATP binding site of CDK4. However, the docking of omeprazole in the CDKs induced conformational changes in their structures, which could potentially affect their function and lead to cell cycle arrest.

Conclusion

Omeprazole, which is a proton pump inhibitor, can induce cell cycle arrest by interacting with the ATP-binding site of CDK4. Moreover, it can also induce conformational changes in CDK2, CDK4, and CDK6 through high-affinity interactions with specific amino acid residues.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cctr/10.2174/0115733947274344231116113325
2024-01-18
2024-11-22

  • From This Site

    /content/journals/cctr/10.2174/0115733947274344231116113325
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LiuF. QuR. YangL. ShiG. HaoS. HuC.J.O. Circular RNA controls tumor occurrence and development via cell cycle regulation.OncoTargets Ther.202215993100910.2147/OTT.S371629
     [Google Scholar]
  2. GousiasK. TheocharousT. SimonM.J.B. Mechanisms of cell cycle arrest and apoptosis in glioblastoma.Biomedicines202210356410.3390/biomedicines10030564
     [Google Scholar]
  3. SchirripaA. SexlV. Cyclin-dependent kinase inhibitors in malignant hematopoiesis.Front. Oncol.202212916682
     [Google Scholar]
  4. SherrC.J. RobertsJ.M.J.G. CDK inhibitors: Positive and negative regulators of G1-phase progression.Genes Dev.1999131215011502
     [Google Scholar]
  5. ClassonM. HarlowE.J.N.R.C. The retinoblastoma tumour suppressor in development and cancer.Nat. Rev. Cancer200221291091710.1038/nrc950
     [Google Scholar]
  6. RoskoskiR. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.Pharmacol. Res.2019139471488
     [Google Scholar]
  7. SanaeiM. Effect of sodium butyrate on p16INK4a, p14ARF, p15INK4b, class I HDACs (HDACs 1, 2, 3) class II HDACs (HDACs 4, 5, 6), cell growth inhibition and apoptosis induction in pancreatic cancer AsPC-1 and colon cancer HCT-116 cell lines.Asian Pac. J. Cancer Prev.2022233795802
     [Google Scholar]
  8. PandaM. KalitaE. RaoA. Mechanism of cell cycle regulation and cell proliferation during human viral infection.Adv. Protein Chem. Struct. Biol.2023135497525
     [Google Scholar]
  9. Ghelli Luserna di RoràA. JandoubiM. MartinelliG. SimonettiG. Targeting proliferation signals and the cell cycle machinery in acute leukemias: Novel molecules on the horizon.Molecules2023283122410.3390/molecules2803122436770891
     [Google Scholar]
  10. GaruttiM. TargatoG. BuriollaS. PalmeroL. MinisiniA.M. PuglisiF.J.C. CDK4/6 inhibitors in melanoma: A comprehensive review.Cells20211061334
     [Google Scholar]
  11. LiuJ-L. MaH-P. LuX-L. SunS-H. GuoX. NF-κB induces abnormal centrosome amplification by upregulation of CDK2 in laryngeal squamous cell cancer.Int. J. Oncol.2011394915924
     [Google Scholar]
  12. ZhangM. ZhangL. HeiR. LiX. CaiH. WuX. CDK inhibitors in cancer therapy, an overview of recent development.Am. J. Cancer Res.202111519131935
     [Google Scholar]
  13. WallmarkB. Mechanism of action of omeprazole.Scand J Gastroenterol198621sup11811610.3109/003655286090908813014640
     [Google Scholar]
  14. PawarS.K. PunithR. NaikR.S. SeetharamappaJ. Spectroscopic and molecular modeling approaches to investigate the binding of proton pump inhibitors to human serum albumin.J. Biomol. Struct. Dyn.201735153205322010.1080/07391102.2016.125133727771990
     [Google Scholar]
  15. LinM.Z. ChaiW.M. Ou-YangC. HuangQ. XuX.H. PengY.Y. Antityrosinase mechanism of omeprazole and its application on the preservation of fresh-cut Fuji apple.Int. J. Biol. Macromol.201811753854510.1016/j.ijbiomac.2018.05.17229803745
     [Google Scholar]
  16. CarteeN.M.P. WangM.M. Binding of omeprazole to protein targets identified by monoclonal antibodies.PLoS One2020159e023946410.1371/journal.pone.023946432946534
     [Google Scholar]
  17. JinU.H. MichelhaughS.K. PolinL.A. ShresthaR. MittalS. SafeS. Omeprazole inhibits glioblastoma cell invasion and tumor growth.Cancers2020128209710.3390/cancers1208209732731514
     [Google Scholar]
  18. FengS. QiuG. YangL. Omeprazole improves chemosensitivity of gastric cancer cells by m6A demethylase FTO-mediated activation of mTORC1 and DDIT3 up-regulation.Biosci. Rep.2021411BSR2020084210.1042/BSR2020084233393595
     [Google Scholar]
  19. LiY. RenB. LiH. LuT. FuR. WuZ. Omeprazole suppresses aggressive cancer growth and metastasis in mice through promoting Snail degradation.Acta Pharmacol. Sin.20224371816182810.1038/s41401‑021‑00787‑134785782
     [Google Scholar]
  20. GoelS. BergholzJ.S. ZhaoJ.J.J.N.R.C. Targeting CDK4 and CDK6 in cancer.Nat. Rev. Cancer202222635637210.1038/s41568‑022‑00456‑3
     [Google Scholar]
  21. SaidM.A. AbdelrahmanM.A. AbourehabM.A. FaresM. A patent review of anticancer CDK2 inhibitors (2017–present).Expert Opin. Ther. Pat.2022328885898
     [Google Scholar]
  22. McInnesC. WangS. AndersonS. O’BoyleJ. JacksonW. KontopidisG. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.Chem. Biol.200411452553410.1016/j.chembiol.2004.03.022
     [Google Scholar]
  23. EchalierA. HoleA.J. LolliG. EndicottJ.A. An inhibitor’s-eye view of the ATP-binding site of CDKs in different regulatory states.ACS Chem. Biol.20149612511256
     [Google Scholar]
  24. SubramanianJ. SharmaS. A novel computational analysis of ligand-induced conformational changes in the ATP binding sites of cyclin dependent kinases.J. Med. Chem.2006491854345441
     [Google Scholar]
  25. NazirY. RafiqueH. RoshanS. ShamasS. AshrafZ. RafiqM. Molecular docking, synthesis, and tyrosinase inhibition activity of acetophenone amide: Potential inhibitor of melanogenesis.BioMed Res. Int.202220221040693
     [Google Scholar]
  26. SilvaLB FerreiraEFB Maryam Galantamine based novel acetylcholinesterase enzyme inhibitors: A molecular modeling design approach.Molecules2023283103510.3390/molecules2803103536770702
     [Google Scholar]
  27. TsengP.S. AndeC. MoremenK.W. CrichD.J.A.C. Influence of side chain conformation on the activity of glycosidase inhibitors.Angew. Chem. Int. Ed. Engl.2023628e202217809
     [Google Scholar]
  28. AhmedM.C. CrehuetR. Lindorff-LarsenK.J.I.D.P.M. Computing, analyzing, and comparing the radius of gyration and hydrodynamic radius in conformational ensembles of intrinsically disordered proteins.Methods Mol. Biol.202021414295
     [Google Scholar]
  29. IttisoponpisanS. IslamS.A. KhannaT. AlhuzimiE. DavidA. Can predicted protein 3D structures provide reliable insights into whether missense variants are disease associated?J. Mol. Biol.20194311121972212
     [Google Scholar]
  30. BaiY. ZhuP. ZhouK. ZhangS-G.J.E. MedicineT. Effect of the acid suppressor omeprazole on the proliferation, migration, invasion and cell cycle of esophageal squamous cell carcinoma cells via the aryl hydrocarbon receptor pathway.Exp. Ther. Med.2021224118710.3892/etm.2021.10621
     [Google Scholar]
  31. HouY. HuQ. HuangJ. Omeprazole inhibits cell proliferation and induces G0/G1 cell cycle arrest through up-regulating miR-203a-3p expression in Barrett’s esophagus cells.Front. Pharmacol.20188968
     [Google Scholar]
  32. MirM.A. JaveedT. Novel CDK inhibitors in breast cancer. In: Therapeutic potential of Cell Cycle Kinases in Breast Cancer.SingaporeSpringer202325326710.1007/978‑981‑19‑8911‑7_12
     [Google Scholar]
/content/journals/cctr/10.2174/0115733947274344231116113325
Loading
The Molecular Docking and Molecular Dynamic Effects of Omeprazole on CDKs 2, 4, and 6 as a Potential CDK Inhibitor in Cancer Treatment
Curr Cancer Ther Rev 21, 110 (2025); https://doi.org/10.2174/0115733947274344231116113325
/content/journals/cctr/10.2174/0115733947274344231116113325
/content/journals/cctr/10.2174/0115733947274344231116113325
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): ATP; Cell cycle; cyclin-depending kinases; molecular dynamics; omeprazole; retinoblastoma protein

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test